Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review
- 22 December 2020
- journal article
- review article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (2), 153-160
- https://doi.org/10.1016/j.clcc.2020.12.002
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic reviewnpj Breast Cancer, 2016
- Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation studyBMC Cancer, 2016
- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer GroupThe Lancet, 2015
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialThe Lancet Oncology, 2013
- Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancerInternational Journal of Cancer, 2010
- Potential Regional Differences for the Tolerability Profiles of FluoropyrimidinesJournal of Clinical Oncology, 2008
- Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group StudyJournal of Clinical Oncology, 2005
- Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2003
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals of Oncology, 2002